Bhatt Padmanabh P. — SEC Form 4 filings
SEC reporting owner CIK 1539215. 27 Form 4 filings on record with FilingPulse; latest filed 2026-08-14.
Transaction summary — filings shown
Covers all 27 filings on record, filed 2024-02-26 to 2026-08-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 19 legs across 11 filings — 240,710 shares, $10,060,180 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 93.
- Largest priced transaction: sale of 34,114 shares @ $50.18 ($1,711,841) in SUPERNUS PHARMACEUTICALS, INC., filed 2026-03-18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Sr. VP of IP, CSO | 27 | — | 19 legs · 240,710 sh · $10,060,180 | 93 |
Form 4 filings — Bhatt Padmanabh P.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-14 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 2,500 @ $0 · Tax withholding (F): 1,158 @ $46.57 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2026-07-31 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 2,500 (derivative) @ $0 | EDGAR |
| 2026-03-18 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 22,750 @ $36.75 · Option exercise (M): 4,250 @ $29.61 · Option exercise (M): 18,000 @ $32.20 · Option exercise (M): 5,000 @ $27.94 · Sale (S): 34,114 @ $50.18 · Sale (S): 15,886 @ $50.49 · +16 more | EDGAR |
| 2026-02-26 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 1,250 @ $0 · Tax withholding (F): 650 @ $50.69 · Disposition to issuer (D): 1,250 (derivative) @ $0 | EDGAR |
| 2026-02-25 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 1,125 @ $0 · Tax withholding (F): 581 @ $51.35 · Grant/award (A): 750 @ $0 · Tax withholding (F): 354 @ $50.86 · Grant/award (A): 1,250 @ $0 · Tax withholding (F): 646 @ $50.86 · +3 more | EDGAR |
| 2026-02-20 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 13,500 (derivative) @ $0 · Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 1,500 @ $0 · Sale (S): 710 @ $44.44 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2025-11-17 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 1,250 @ $0 · Tax withholding (F): 581 @ $41.46 · Option exercise (M): 1,250 (derivative) @ $0 | EDGAR |
| 2025-08-08 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 1,250 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Tax withholding (F): 335 @ $33.05 · Tax withholding (F): 575 @ $33.05 · Tax withholding (F): 575 @ $33.05 | EDGAR |
| 2025-02-24 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 1,650 @ $0 · Tax withholding (F): 860 @ $39.15 · Grant/award (A): 750 @ $0 · Grant/award (A): 1,250 @ $0 · Grant/award (A): 1,250 @ $0 · Option exercise (M): 1,650 (derivative) @ $0 · +3 more | EDGAR |
| 2025-02-21 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 20,000 (derivative) @ $0 · Grant/award (A): 4,500 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4/A | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 700 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 9,477 @ $29.61 · Sale (S): 9,477 @ $39.70 · Option exercise (M): 9,477 (derivative) @ $0 | EDGAR |
| 2025-01-29 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 2,573 @ $29.61 · Sale (S): 2,573 @ $39.62 · Option exercise (M): 700 @ $29.61 · Sale (S): 700 @ $39.62 · Option exercise (M): 2,573 (derivative) @ $0 · Grant/award (A): 1,650 (derivative) @ $0 · +1 more | EDGAR |
| 2024-12-04 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 8,750 @ $23.99 · Sale (S): 8,750 @ $36.68 · Option exercise (M): 12,745 @ $25.30 · Sale (S): 12,745 @ $36.68 · Option exercise (M): 8,750 (derivative) @ $0 · Option exercise (M): 12,745 (derivative) @ $0 | EDGAR |
| 2024-08-20 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 1,250 @ $0 · Tax withholding (F): 572 @ $29.57 · Option exercise (M): 1,250 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 1,250 (derivative) @ $0 | EDGAR |
| 2024-03-25 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 14,491 @ $25.30 · Sale (S): 14,491 @ $35.31 · Option exercise (M): 14,491 (derivative) @ $0 | EDGAR |
| 2024-03-22 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 400 @ $25.30 · Sale (S): 400 @ $35.31 · Option exercise (M): 400 (derivative) @ $0 | EDGAR |
| 2024-03-21 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 12,364 @ $25.30 · Sale (S): 12,364 @ $35.31 · Option exercise (M): 12,364 (derivative) @ $0 | EDGAR |
| 2024-03-15 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 26,250 @ $23.99 · Sale (S): 26,250 @ $34.10 · Option exercise (M): 36,116 @ $12.98 · Sale (S): 36,116 @ $33.48 · Option exercise (M): 36,116 (derivative) @ $0 · Option exercise (M): 26,250 (derivative) @ $0 | EDGAR |
| 2024-03-14 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 3,884 @ $12.98 · Sale (S): 3,884 @ $32.99 · Option exercise (M): 3,884 (derivative) @ $0 | EDGAR |
| 2024-02-28 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 5,000 @ $9.13 · Sale (S): 5,000 @ $30.21 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-02-27 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 1,250 @ $0 · Tax withholding (F): 638 @ $29.06 · Disposition to issuer (D): 1,250 (derivative) @ $0 | EDGAR |
| 2024-02-26 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 750 @ $0 · Tax withholding (F): 372 @ $27.94 · Disposition to issuer (D): 750 (derivative) @ $0 · Grant/award (A): 5,000 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1539215 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →